Effective, Affordable and Reliable Antivenoms readily available

MADRID, Sept. 10, 2015 /PRNewswire/ -- The apparent shortage of effective antivenoms and their lack of reliable supply in the regions of the world that need them most is a widely recognized global problem. INOSAN BIOPHARMA is dedicated to providing an affordable solution that can reduce or eliminate the unnecessary loss of human life. The company is currently shipping field-ready snake, scorpion and spider antivenoms that are more effective and affordable than older technologies.

INOSAN BIOPHARMA has developed an innovative line of region-specific antivenoms for Africa (North Africa and the Middle East, Sub-Saharan Africa), Eurasia (Europe and Western Asia) and North America. These products have demonstrated high effectiveness at neutralizing the venom of dangerous endemic species.

INOSAN BIOPHARMA antivenoms far exceed World Health Organization regulations for safety and effectiveness. With more than 100,000 vials used so far for successful human treatment worldwide, their qualities are more than proven in the field.

Years of proprietary research and development went into creating a new manufacturing process for these antivenoms. They have one-third the protein content of previous generations, yet are more potent. This greatly reduces the risk of adverse patient reactions. These innovations are the reason INOSAN BIOPHARMA designates its antivenoms "High Specificity Immunotherapic Polyvalent F(ab')₂".

This proprietary technology also allows INOSAN BIOPHARMA to include antibodies for multiple kinds of venoms in the same vial, and have a reliable and consistent high-yield production process.

So far INOSAN BIOPHARMA has been successful at meeting the demands of their clients worldwide.

These antivenoms are delivered as a lyophilized powder (freeze dried) that is highly tolerant to extreme temperatures, making them resilient and inexpensive to transport.

INOSAN BIOPHARMA's products have been approved by the health authorities of several countries and are already in use in the following nations: Chad, Algeria, Morocco, Benin, Mali, Togo, Ivory Coast, Senegal, Kenya, Ghana, Uganda, Guinea Conakry, Mauritania, South Africa, Republic of Congo, Democratic Republic of Congo, Ethiopia, Gabon, Palestine, Iraq (Ministry of Health and US Army), Afghanistan (US Army) and the United Arab Emirates. INOSAN BIOPHARMA is in the process of gaining approval for commercialization in: Angola, Burkina Faso, the Central African Republic, Cameroon, Jordan, the Netherlands, Colombia and Mexico.

Prestigious international health organizations are actively purchasing, stocking and using INOSAN BIOPHARMA antivenoms. Among them are the World Health Organization, UNICEF, Medecins du Monde, Institut Pasteur d'Algerie, Institut Pasteur du Maroc, PNA Senegal, CAME Benin, CAMEG Togo, Eurapharma and Planetpharma.

For a reference on our products please read "Evaluation of a new polyvalent antivenom against snakebite envenomation (INOSERP™ Panafrica) in two different epidemiological settings: Northern Benin and Maritime Guinea" by Chippaux J.-P., Balde M.C., Sessinou E., Yero Boiro M. and Massougbodji A. published in the journal Medecine et Sante Tropicales on September 2014. It presents the results of a recent study evaluating the safety and efficacy of one of INOSAN BIOPHARMA's snake antivenoms, INOSERP™ Panafrica.

Both governments and private institutions have repeatedly confirmed that INOSAN BIOPHARMA is today's reliable resource for antivenins.

For more information, please contact:

[email protected]
Tel. +52-55-50-03-00-00                                                      
www.inosanbiopharma.com

SOURCE INOSAN BIOPHARMA, S.A.

Related Links

http://www.inosanbiopharma.com